Insmed Inc. (Nasdaq: INSM) will conduct two Phase 3 studies of its inhaled antibiotic Arikayce which disappointed investors who had hoped for regulatory approval without additional clinical trials. Shares of the biopharmaceutical plummeted $4.28 to close at $12.97.
More trials for Insmed's Arikayce
August 04, 2014 at 12:53 PM EDT